CFO transition in Senzime
Jessica Roxhed has today communicated that she will leave the company for personal reasons since she intends to start a new career.
Pia Renaudin, Senzimes CEO, commented:” Jessica has been a very valuable member of the management team during these initial years of building the company, and I wish her all the best in her upcoming career change. Senzime is in a new, expansive phase focusing on global commercialization of TetraGraph and I look forward to initiating the recruitment of a CFO with an experience that matches the company's future needs”.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com